Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)
ACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.
Media Articles Related to Accolate (Zafirlukast)
Childhood Asthma Linked to Increased Migraine Risk
Source: Medscape Allergy & Clinical Immunology Headlines [2017.02.23]
Results of a new study show children with asthma have an increased risk for migraine, but those receiving asthma treatments have a decreased migraine risk.
Medscape Medical News
Prenatal PUFAs and Asthma/Wheeze in Offspring
Source: Medscape Allergy & Clinical Immunology Headlines [2017.02.21]
Does PUFA supplementation in the third trimester significantly reduce childhood asthma/wheeze, or is this just another fish story?
iMedical Apps: CoherentRx for Asthma Patient Education
Source: MedPage Today Allergy & Immunology [2017.02.21]
(MedPage Today) -- High-quality tool that draws on reputable sources
There's Fun and Fitness in the Pool for Asthmatic Kids
Source: MedicineNet Exercise and Activity Specialty [2017.02.21]
Title: There's Fun and Fitness in the Pool for Asthmatic Kids
Category: Health News
Created: 2/20/2017 12:00:00 AM
Last Editorial Review: 2/21/2017 12:00:00 AM
Babies with gut yeast may be at risk of asthma
Source: Respiratory / Asthma News From Medical News Today [2017.02.17]
A new study suggests a fungus known as Pichia - found in babies' guts - may increase the risk of developing childhood asthma, if acquired in early life.
Published Studies Related to Accolate (Zafirlukast)
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. [2011.02]
PURPOSE: Gemfibrozil, a strong inhibitor of cytochrome P450 (CYP) 2C8 in vivo, was recently found to markedly increase the plasma concentrations of montelukast in humans. Like montelukast, zafirlukast is a substrate of CYP2C9 and CYP3A4 and a potent inhibitor of CYP2C8 in vitro. To investigate the contribution of CYP2C8 to the metabolism of zafirlukast in vivo, we studied the effect of gemfibrozil on the pharmacokinetics of zafirlukast... CONCLUSIONS: Gemfibrozil has no effect on the pharmacokinetics of zafirlukast, indicating that CYP2C8 does not play a significant role in the elimination of zafirlukast.
Effects of zafirlukast on capsular contracture: controlled study measuring the mammary compliance. [2007.07]
Capsular contracture is a highly distressing, difficult complication after breast augmentation for both the patient and the surgeon.The present study suggests that zafirlukast may be effective in reducing pain and breast capsule distortion in patients with longstanding contracture who are either not surgical candidates or who do not wish to undergo surgery.
[Nasal budesonide plus zafirlukast vs nasal budesonide plus loratadine-pseudoephedrine for controlling the symptoms of rhinitis and asthma] [2005.03]
OBJECTIVE: To compare the efficacy of nasal budesonide plus oral zafirlukast against nasal budesonide plus oral loratadine/pseudoephedrine combination in the control of symptoms of rhinitis and asthma... CONCLUSIONS: The association of a nasal steroid with a leukotriene modifier (zafirlukast) was more effective for controlling nasal symptoms and especially bronchial symptoms than the association of a nasal steroid with antihistamines (loratadine) with pseudoephedrine. Other inflammation indicators, such as eosinophilia and nasal eosinophilia, were diminished; the VEF1 increased significantly in both treatment groups. All the above may be due to the nasal steroid use associated to a leukotriene modifier.
Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. [2005.03]
The cause of category III A prostatitis, chronic prostatitis/chronic male pelvic pain syndrome category A (CP/CPPS A), is uncertain... The problems of recruitment into this study (in spite of a large number of patients with prostatic type pain being seen in our unit) suggest that multicentre treatment trials using non-invasive diagnostic techniques such as the CPSI (rather than single GU medicine units diagnosing CP/CPPS A by uncomfortable direct prostatic testing) are likely to be the most effective and objective methods of undertaking treatment trials in the CP/ CPPS A field in the future.
Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. [2005.02]
BACKGROUND: We have shown that inhalation of leukotriene (LT) E 4 contributes to specific recruitment of eosinophils to the airway mucosa in patients with asthma at the time of maximal decrease in airway-specific conductance. OBJECTIVE: We examined the ability of the cysteinyl LT 1 receptor antagonist, zafirlukast, to improve or prevent LT-mediated eosinophilia and airway obstruction in asthma... CONCLUSION: Persistent LTE 4 -induced airway eosinophilia may form the basis of an amplification mechanism for further eosinophil recruitment. Zafirlukast prevents LTE 4 -induced eosinophilic airway inflammation in mild asthma.
Clinical Trials Related to Accolate (Zafirlukast)
Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition [Completed]
The objective of this study was to compare the relative bioavailability of zafirlukast
tablets 20 mg with that of 'ACCOLATEŽ' tablets 20 mg (zafirlukast tablets 20 mg) in healthy,
adult, human, subjects under fasting conditions and to monitor safety of subjects.
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy [Completed]
This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants
who completed the EXCELS study (NCT00252135) and had received long-term treatment with
Xolair. In addition, participants who did not participate in the EXCELS study but received
long-term (~5 years) treatment with Xolair were allowed to enter the study.
Reports of Suspected Accolate (Zafirlukast) Side Effects
Drug Dose Omission (25),
Chronic Obstructive Pulmonary Disease (10),
Diabetes Mellitus (9),
Drug Ineffective (8),
Multiple Allergies (8), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Accolate has an overall score of 1. The effectiveness score is 2 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Accolate review by 44 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Capsuar Contracture of Breast Implant|
|Dosage & duration:|| || 20mg taken twice daily for the period of 3 months|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || The benefits were not good, and this drug was very expensive and was not effective at all for the problem I was experiencing. At the time when I was experiencing complications from the implants, I truly believed that my Doctor did not prescribed the drug in time. The literature I read on this drug claims that it is more likely to work if used early in the treatment of Capsular Contracture.|
|Side effects:|| || I tolerated the medication very well. I didn't experience any illness or side effects from Accolate. I felt a strong mental negativity towards the drug when it was prescribed based on the literature I read and my Doctor's statement about being treated early. I think I tried the treatment knowing in my mind that it was not going to work. |
|Comments:|| || I was required to take Accolate for three months to promote softening of my Breast Implants. The 20mg tablets were to be taken twice daily along with continued daily massage of my breasts. My Doctor said that the treatment had more chances of being effective if used early in detecting the Capsular Contracture (My treatment was started 5 months after the breast implant surgery). If the treatment didn't work, he advised, I would need surgery.|
Page last updated: 2017-02-23